Advertisement

Sjögren's Syndrome

  • Manuel Ramos-Casals
  • Troy E. Daniels
  • Robert I. Fox
  • John P. Whitcher
  • George E. Fragoulis
  • Fotini N. Skopouli
  • Haralampos M. Moutsopoulos

Abstract

Primary Sjögren's syndrome (SjS) is a systemic autoimmune disease that is associated with early and gradually progressive lacrimal and salivary dysfunction. Secondary SjS occurs in association with other autoimmune disorders, the most common of which is rheumatoid arthritis. About 90% of patients with SjS are women. Minor salivary glands and lacrimal glands in SjS exhibit a particular pattern of periductal focal lymphocytic infiltration known as focal lymphocytic sialadenitis. Primary SjS has a community prevalence that ranges from 0.1 to 0.6%. The major eye problem in SjS is keratoconjunctivitis sicca, which leads to xerophthalmia. The principal oral manifestation of SjS is decreased salivary gland production, leading to xerostomia and a predilection for dental caries. Extraglandular manifestations of SjS include arthral-gias, thyroiditis, renal involvement (leading to renal tubular acidosis (RTA)), peripheral neuropathy, cutaneous vasculitis, and lymphoma. The risk of lymphoma in SjS is approximately 5%. Most patients with SjS develop increased circulating polyclonal immunoglobulins and autoantibodies. These autoantibodies include two fairly specific antibodies directed against the Ro (SS-A) and La (SS-B) antigens.

Keywords

Salivary Gland Mixed Cryoglobulinemia Burning Mouth Syndrome Keratoconjunctivitis Sicca Gland Enlargement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abraham CM, al-Hashimi I, Haghighat N. Evaluation of the levels of oral Candida in patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86:65–8PubMedCrossRefGoogle Scholar
  2. Alexander E, Arnett F, Provost T, Stevens MB. Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hemato-logic abnormalities, and serologic hyperactivity. Ann Intern Med. 1983;98:155–9PubMedCrossRefGoogle Scholar
  3. Alexander EL, Beall SjS, Gordon B, et al Magnetic resonance imaging of cerebral lesions in patients with the Sjögren syndrome. Ann Intern Med. 1988;108:815–23PubMedCrossRefGoogle Scholar
  4. Almstahl A, Kroneld U, Tarkowski A, Wikstrom M. Oral microbial flora in Sjögren's syndrome. J Rheumatol. 1999;26:110–4PubMedGoogle Scholar
  5. Andonopoulos AP, Drosos AA, Skopouli FN, Acritidis NC, Moutsopoulos HM. Secondary Sjögren's syndrome in rheumatoid arthritis. J Rheumatol. 1987;14:1098–103PubMedGoogle Scholar
  6. Andonopoulos AP, Drosos AA, Skopouli FN, Moutsopoulos HM. Sjögren's syndrome in rheumatoid arthritis and progressive systemic sclerosis. A comparative study. Clin Exp Rheumatol. 1989;7: 203–5PubMedGoogle Scholar
  7. Aoki N. Klinefelter's syndrome, autoimmunity, and associated endo-crinopathies. Intern Med. 1999;38:838–9PubMedCrossRefGoogle Scholar
  8. Atalar K, Afzali B, Lams B, et al Falls, hypokalaemia, and a dry mouth. Lancet. 2007;370(9582):192PubMedCrossRefGoogle Scholar
  9. Belafsky PC, Postma GN. The laryngeal and esophageal manifestations of Sjögren's syndrome. Curr Rheumatol Rep. 2003;5:297–303PubMedCrossRefGoogle Scholar
  10. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjögren's syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore). 1965;44:187–231PubMedGoogle Scholar
  11. Boki KA, Ioannidis JP, Segas JV, et al How significant is sensorineural hearing loss in primary Sjögren's syndrome? J Rheumatol. 2001;28: 798–801PubMedGoogle Scholar
  12. Bossini N, Savoldi S, Franceschini F, et al Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. Nephrol Dial Transplant. 2001;16:2328–36PubMedCrossRefGoogle Scholar
  13. Boutsi EA, Paikos S, Dafni UG, et al Dental and periodontal status of Sjögren's syndrome. J Clin Periodontol. 2000;27:231–5PubMedCrossRefGoogle Scholar
  14. Bowman SK, Ibrahim GH, Holmes G, et al Estimating the prevalence among Caucasian women of primary Sjögren's syndrome in two general practices in Birmingham, UK Scand J Rheumatol. 2004;33: 39–43Google Scholar
  15. Brito-Zerón P, Ramos-Casals M, Bove A, et al Predicting adverse outcomes in primary Sjögren's syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007;46(8):1359–62CrossRefGoogle Scholar
  16. Brito-Zerón P, Ramos-Casals M, Nardi N, et al Circulating monoclonal immunoglobulins in Sjögren syndrome: prevalence and clinical significance in 237 patients. Medicine (Baltimore). 2005;84(2): 90–7CrossRefGoogle Scholar
  17. Brito-Zerón P, Soria N, Muñoz S, et al Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjögren's syndrome. Semin Arthritis Rheum. 2008;38(5):389–95PubMedCrossRefGoogle Scholar
  18. Caporali R, Bonacci E, Epis O, et al Safety and usefulness of minor salivary gland biopsy: retrospective analysis of 502 procedures performed at a single center. Arthritis Rheum. 2008;59:714–20PubMedCrossRefGoogle Scholar
  19. Chai J, Herrmann DN, Stanton M, et al Painful small-fiber neuropathy in Sjögren's syndrome. Neurology. 2005;65:925–7PubMedCrossRefGoogle Scholar
  20. Collard RC, Koehler RP, Mattson DH. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology. 1997;49: 857–61PubMedCrossRefGoogle Scholar
  21. Coppo P, Sibilia J, Maloisel F, et al Primary Sjögren's syndrome associated agranulocytosis: a benign disorder? Ann Rheum Dis. 2003;62: 476–8PubMedCrossRefGoogle Scholar
  22. Cummings NA, Schall GL, Asofski R. Sjögren's syndrome. New aspects of research, diagnosis and therapy. Ann Intern Med. 1971;75: 937CrossRefGoogle Scholar
  23. Dafni UG, Tzioufas AG, Staikos P, et al Prevalence of Sjögren's syndrome in a closed rural community. Ann Rheum Dis. 1997;56: 521–5PubMedCrossRefGoogle Scholar
  24. Daniels T, Greenspan JS, Cox D, Criswell LA, DeSouza Y, Dong Y, et al Objective measures in Sjögren's syndrome are strongly associated with each other but not with sicca symptoms: analysis of 564 enrollees in the SICCA international registry and repository. Arthritis Rheum. 2007;56 Suppl:S446Google Scholar
  25. Daniels T, Whitcher J. Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjögren's syndrome. Arthritis Rheumatol. 1994;37:869–77CrossRefGoogle Scholar
  26. Daniels TE. Benign lymphoepithelial lesion and Sjögren's syndrome. Ch 6. In Ellis GL, Auclair PL, Gnepp DR, editors. Surgical pathology of the salivary glands. Philadelphia: W.B.Saunders; 1991. p. 83–106Google Scholar
  27. Daniels TE, Fox PC. Salivary and oral components of Sjögren's syndrome. Rheum Dis Clin North Am. 1992;18(3):571–89PubMedGoogle Scholar
  28. Daniels TE, Silverman S, Michalski JP, Greenspan JS, Sylvester RA, Talal N. The oral component of Sjögren's syndrome. Oral Surg Oral Med Oral Pathol. 1975;39:875–85PubMedCrossRefGoogle Scholar
  29. Daniels TE. Evaluation, differential diagnosis, and treatment of xerostomia. J Rheumatol. 2000;27(Suppl 61):6–10Google Scholar
  30. Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjögren's syndrome. Ann Rheum Dis. 2000;59:709–12PubMedCrossRefGoogle Scholar
  31. Dawson LJ, Caulfield VL, Stanbury JB, et al Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford). 2005;44:449–55CrossRefGoogle Scholar
  32. Delalande S, de Seze J, Fauchais AL. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83:280–91PubMedCrossRefGoogle Scholar
  33. Denislic M, Meh D. Early asymmetric neuropathy in primary Sjögren's syndrome. J Neurol. 1997;244(6):383–7PubMedCrossRefGoogle Scholar
  34. Drosos AA, Voulgari PV, Psychos DN, Tsifetaki N, Bai M. Sicca syndrome in patients with sarcoidosis. Rheumatol Int. 1999;18: 177–80PubMedCrossRefGoogle Scholar
  35. Dyck PJ. The clinical heterogeneity of immune sensory and autonomic neuropathies with (or without) sicca. Brain. 2005;128(Pt 11): 2480–2CrossRefGoogle Scholar
  36. Ferreira S, D'Cruz DP, Hughes GR. Multiple sclerosis, neuropsychiat-ric lupus and antiphospholipid syndrome: where do we stand? Rheumatology (Oxford). 2005;44:434–42CrossRefGoogle Scholar
  37. Font J, Ramos-Casals M, Cervera R, et al Antineutrophil cytoplasmic antibodies in primary Sjögren's syndrome: prevalence and clinical significance. Br J Rheumatol. 1998;37(12):1287–91PubMedCrossRefGoogle Scholar
  38. Font J, Ramos-Casals M, de la Red G, et al Pure sensory neuropathy in primary Sjögren's syndrome. Longterm prospective followup and review of the literature. J Rheumatol. 2003;30(7):1552–7PubMedGoogle Scholar
  39. Forstot JZ, Forstot SL, Greer RO, Tan EM. The incidence of Sjögren's sicca complex in a population of patients with keratoconjunctivitis sicca. Arthritis Rheumat. 1982;25:156–60PubMedCrossRefGoogle Scholar
  40. Fox RI, Stern M. Sjögren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol Suppl 2002;(116):3–13Google Scholar
  41. Franquet T, Diaz C, Domingo P, et al Air trapping in primary Sjögren syndrome: correlation of expiratory CT with pulmonary function tests. J Comput Assist Tomogr. 1999;23:169–73PubMedCrossRefGoogle Scholar
  42. Freeman SR, Sheehan PZ, Thorpe MA, Rutka JA. Ear, nose, and throat manifestations of Sjögren's syndrome: retrospective review of a multidisciplinary clinic. J Otolaryngol. 2005;34(1):20–4PubMedCrossRefGoogle Scholar
  43. García-Carrasco M, Ramos-Casals M, et al Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002a;81(4):270–80CrossRefGoogle Scholar
  44. García-Carrasco M, Sisó A, Ramos-Casals M, et al Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol. 2002b;29: 726–30Google Scholar
  45. Gerli R, Muscat C, Giansanti M, et al Quantitative assessment of salivary gland inflammatory infiltration in primary Sjögren's syndrome: its relationship to different demographic, clinical and serological features of the disorder. Br J Rheumatol. 1997;36:969–75PubMedCrossRefGoogle Scholar
  46. Gøransson LG, Herigstad A, Tjensvoll AB, et al Peripheral neuropathy in primary Sjögren syndrome: a population-based study. Arch Neurol. 2006;63:1612–5PubMedCrossRefGoogle Scholar
  47. Gorson KC, Ropper AH. Muscle Nerve 2003; 28(5):553–60. Positive salivary gland biopsy, Sjögren syndrome, and neuropathy: clinical implicationsPubMedCrossRefGoogle Scholar
  48. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007; 35(1):66–9PubMedCrossRefGoogle Scholar
  49. Goules A, Masouridi S, Tzioufas AG, et al Clinically significant and biopsy-documented renal involvement in primary Sjögren's syndrome. Medicine (Baltimore). 2000;79:241–9CrossRefGoogle Scholar
  50. Hakansson U, Jacobsson L, Lilja B, et al Salivary gland scintigraphy in subjects with and without symptoms of dry mouth and/or eyes, and, in patients with primary Sjögren's syndrome. Scand J Rheumatol. 1994;23:326–33PubMedCrossRefGoogle Scholar
  51. Helman J, Turner RJ, Fox PC, Baum BJ. 99mTc-pertechnetate uptake in parotid acinar cells by the Na + /K + /Cl- co- transport system. J Clin Invest. 1987;79:1310–3PubMedCrossRefGoogle Scholar
  52. Hernandez YL, Daniels TE. Oral candidiasis in Sjögren's syndrome: prevalence, clinical correlations, and treatment. Oral Surg Oral Med Oral Pathol. 1989;3:324–9CrossRefGoogle Scholar
  53. Hershkovich O, Shafat I, Nagler RM. Age-related changes in salivary antioxidant profile: possible implications for oral cancer. J Gerontol A Biol Sci Med Sci. 2007;62:361–6PubMedCrossRefGoogle Scholar
  54. Hyer S, Kong A, Pratt B, et al Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol). 2007;19: 83–6CrossRefGoogle Scholar
  55. Ioannidis JP, Moutsopoulos HM. Sjögren's syndrome: too many associations, too limited evidence. The enigmatic example of CNS involvement. Semin Arthritis Rheum. 1999;29:1–3CrossRefGoogle Scholar
  56. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum. 2002;46:741–7PubMedCrossRefGoogle Scholar
  57. Jacobsson LT, Axell TE, Hansen BU, et al Dry eyes or mouth: an epide-miological study in Swedish adults, with special reference to primary Sjögren's syndrome. J Autoimmun. 1989;2:521–7PubMedCrossRefGoogle Scholar
  58. Jara LJ, Navarro C, Brito-Zeron P, et al Thyroid disease in Sjögren's syndrome. Clin Rheumatol. 2007;26:1601–6PubMedCrossRefGoogle Scholar
  59. Jungehulsing M, Fischbach R, Schroder U, et al Magnetic resonance sialography. Otolaryngol Head Neck Surg. 1999;121:488–94PubMedCrossRefGoogle Scholar
  60. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol. 2006;41:613–25PubMedCrossRefGoogle Scholar
  61. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89:888–92PubMedCrossRefGoogle Scholar
  62. Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum 1985; 28:1128–32PubMedCrossRefGoogle Scholar
  63. Kohn WG, Ship JA, Atkinson JC, et al Salivary gland 99mTc-scintigra-phy: a grading scale and correlation with major salivary gland flow rates. J Oral Pathol Med. 1992;21:70–4PubMedCrossRefGoogle Scholar
  64. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev. 2007;220:251–69PubMedCrossRefGoogle Scholar
  65. Kruize AA, Hené RJ, Kallenberg CG, et al Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year, double-blind crossover trial. Ann Rheum Dis. 1993;52:360–4PubMedCrossRefGoogle Scholar
  66. Kruize AA, Hene RJ, van der Heide A, Bodeutsch C, deWilde PCM, vanBijsterveld OP, et al Long-term followup of patients with Sjögren's syndrome. Arthritis Rheum. 1996;297–303Google Scholar
  67. Lamour A, Le Corre R, Pennec YL, Cartron J, Youinou P. Heterogeneity of neutrophil antibodies in patients with primary Sjögren's syndrome. Blood. 1995;86:3553–9PubMedGoogle Scholar
  68. Larsson X, Bredberg A, Henriksson G, Manthorpe R, Sallmyr A. Immunohistochemistry of the B cell component in lower lip salivary glands of Sjögren's syndrome and healthy subjects. Scand J Immunol. 2005;61:98–107PubMedCrossRefGoogle Scholar
  69. Lekhanont K, Leyngold IM, Suwan-Apichon O, et al Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model. Cornea. 2007;26: 84–9PubMedCrossRefGoogle Scholar
  70. Leppilahti M, Tammela TL, Huhtala H, et al Interstitial cystitis-like urinary symptoms among patients with Sjögren's syndrome: a population-based study in Finland. Am J Med. 2003;115:62–5PubMedCrossRefGoogle Scholar
  71. Liang L, Zhang M, Zou W, Liu Z. Aggravated dry eye after laser in situ keratomileusis in patients with Sjögren syndrome. Cornea. 2008;27: 120–3PubMedCrossRefGoogle Scholar
  72. Makula E, Pokorny G, Kiss M, et al The place of magnetic resonance and ultrasonographic examinations of the parotid gland in the diagnosis and follow-up of primary Sjögren's syndrome. Rheumatology (Oxford). 2000;39:97–104CrossRefGoogle Scholar
  73. Maltsman-Tseikhin A, Moricca P, Niv D. Burning mouth syndrome: will better understanding yield better management? Pain Pract. 2007; 7:151–62PubMedCrossRefGoogle Scholar
  74. Mandl T, Ekberg O, Wollmer P, et al Dysphagia and dysmotility of the pharynx and oesophagus in patients with primary Sjögren's syndrome. Scand J Rheumatol. 2007a;36:394–401CrossRefGoogle Scholar
  75. Mandl T, Wollmer P, Manthorpe R, Jacobsson LT. Autonomic and orthostatic dysfunction in primary Sjögren's syndrome. J Rheumatol. 2007b;34:1869–74Google Scholar
  76. Manoussakis MN, Georgopoulou C, Zintzaras E, et al Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome. Arthritis Rheum. 2004;50:882–91PubMedCrossRefGoogle Scholar
  77. Mariette X, Agbalika F, Zucker-Franklin D, et al Detection of the tax gene of HTLV-I in labial salivary glands from patients with Sjögren's syndrome and other diseases of the oral cavity. Clin Exp Rheumatol. 2000;18:341–7PubMedGoogle Scholar
  78. Mariette X, Ravaud P, Steinfeld S, et al Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSjS). Arthritis Rheum. 2004;50:1270–6PubMedCrossRefGoogle Scholar
  79. Mariette X, Roux S, Zhang J, et al The level of BlyS (BAFF) correlates with the titer of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis. 2003;62:168–71PubMedCrossRefGoogle Scholar
  80. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's syndrome. Nat Clin Pract Rheumatol. 2006;2: 252–61PubMedCrossRefGoogle Scholar
  81. Mellgren SI, Goransson LG, Omdal R. Primary Sjögren's syndrome associated neuropathy. Can J Neurol Sci. 2007;34:280–7PubMedGoogle Scholar
  82. Mikulicz J. Über eine eigenartige symmetrische Erkrankung der Tranen und Mundspeicheldrusen. Stuttgart: Beitr Chir Fortsch Gewidmet Theodor Billroth. 1892;610–30Google Scholar
  83. Mitsias D, Tzioufas A, Veiopoulou C, et al The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren's syndrome. Clin Exp Immunol. 2002;128:562–8PubMedCrossRefGoogle Scholar
  84. Mori K, Iijima M, Sugiura M et al Sjögren's syndrome associated painful sensory neuropathy without sensory ataxia. J Neurol Neurosurg Psychiatry 2003; 74(9):1320–2PubMedCrossRefGoogle Scholar
  85. Mori K, Iijima M, Koike H, et al The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy. Brain. 2005;128:2518–34PubMedCrossRefGoogle Scholar
  86. Moutsopoulos HM, Balow JE, Lawley TJ, et al Immune complex glom-erulonephritis in sicca syndrome. Am J Med. 1978;64:955–60PubMedCrossRefGoogle Scholar
  87. Moutsopoulos HM, Elkon KB, Mavridis AK, et al Serum C-reactive protein in primary Sjögren's syndrome. Clin Exp Rheumatol. 1983a;1:57–8Google Scholar
  88. Moutsopoulos HM, Webber BL, Vlagopoulos TP, et al Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med. 1979;66:733–6PubMedCrossRefGoogle Scholar
  89. Moutsopoulos HM, Steinberg AD, Fauci AS, et al High incidence of free monoclonal lambda light chains in the sera of patients with Sjögren's syndrome. J Immunol. 1983b;130:2663–5Google Scholar
  90. Moutsopoulos HM, Costello R, Drosos AA, et al Demonstration and identification of monoclonal proteins in the urine of patients with Sjögren's syndrome. Ann Rheum Dis. 1985;44:109–12PubMedCrossRefGoogle Scholar
  91. Nagler RM. Salivary glands and the aging process: mechanistic aspects, health-status and medicinal-efficacy monitoring. Biogerontology. 2004;5:223–33PubMedCrossRefGoogle Scholar
  92. Nakamura H, Kawakami A, Tominaga M, et al Relationship between Sjögren's syndrome and human T-lymphotropic virus type I infection: follow-up study of 83 patients. J Lab Clin Med. 2000;135: 139–44PubMedCrossRefGoogle Scholar
  93. Nardi N, Brito-Zerón P, Ramos-Casals M, et al Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren's syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol. 2006;25(3):341–6PubMedCrossRefGoogle Scholar
  94. Papiris SA, Maniati M, Constantopoulos SH, et al Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann Rheum Dis. 1999;58:61–4PubMedCrossRefGoogle Scholar
  95. Paschides CA, Kitsios G, Karakostas KX, et al Evaluation of tear break-up time, Schirmer's-I test and rose bengal staining as confirmatory tests for keratoconjunctivitis sicca. Clin Exp Rheumatol. 1989;7:155–7PubMedGoogle Scholar
  96. Patton LL, Siegel MA, Benoliel R, De Laat A. Management of burning mouth syndrome: systematic review and management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103 Suppl:S39.e1–13Google Scholar
  97. Pavlidis NA, Karsh J, Moutsopoulos HM. The clinical picture of primary Sjögren's syndrome: a retrospective study. J Rheumatol. 1982;9: 685–90PubMedGoogle Scholar
  98. Pertovaara M, Pukkala E, Laippala P, et al A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis. 2001; 60:467–72PubMedCrossRefGoogle Scholar
  99. Pflugfelder SC, Maskin SL, Anderson B, et al A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444–57PubMedCrossRefGoogle Scholar
  100. Pillemer SR, Smith J, Fox PC, Bowman SJ. Outcome measures for Sjögren's syndrome. J Rheumatol. 2005;32:143–9PubMedGoogle Scholar
  101. Prochorec-Sobieszek M, Wagner T, Loukas M, Chwali ska-Sadowska H, Olesi ska M. Histopathological and immunohistochemical analysis of lymphoid follicles in labial salivary glands in primary and secondary Sjögren's syndrome. Med Sci Monit. 2004;10: BR115–21PubMedGoogle Scholar
  102. Ramos-Casals M, Anaya JM, García-Carrasco M, et al Cutaneous vascu-litis in primary Sjögren syndrome: classification and clinical signifi-cance of 52 patients. Medicine (Baltimore). 2004a;83(2): 96–106CrossRefGoogle Scholar
  103. Ramos-Casals M, Font J, Garcia-Carrasco M, et al Primary Sjögren syndrome: hematologic patterns of disease expression. Medicine (Baltimore). 2002;81(4):281–92CrossRefGoogle Scholar
  104. Ramos-Casals M, García-Carrasco M, Cervera R, et al Thyroid disease in primary Sjögren syndrome: study in a series of 160 patients. Medicine (Baltimore). 2000;79(2):103–8CrossRefGoogle Scholar
  105. Ramos-Casals M, la Civita L, De Vita S, et al For the SjS-HCV Study Group. Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection. Arthritis Rheum. 2007;57(1):161–70PubMedCrossRefGoogle Scholar
  106. Ramos-Casals M, Loustaud-Ratti V, De Vita S, et al For the Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore). 2005;84(2):81–9CrossRefGoogle Scholar
  107. Ramos-Casals M, Nardi N, Brito-Zerón P, et al Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum. 2006a; 35(5): 312–21CrossRefGoogle Scholar
  108. Ramos-Casals M, Sánchez-Tapias JM, Parés A, et al Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome. J Rheumatol. 2006b;33(8): 1593–9Google Scholar
  109. Ramos-Casals M, Solans R, Rosas J, et al Primary Sjögren syndrome in Spain: clinical and immunologic expression of 1010 patients. Medicine (Baltimore). 2008;87(4):210–9CrossRefGoogle Scholar
  110. Reinertsen JL, Schaefer EJ, Brewer HB, Moutsopoulos HM. Sicca-like syndrome in type V hyperlipoproteinemia. Arthritis Rheum. 1980;23: 114–8PubMedCrossRefGoogle Scholar
  111. Rhodus NL, Michalowicz BS. Periodontal status and sulcular Candida albicans colonization in patients with primary Sjögren's syndrome. Quintessence Int. 2005;36(3):228–33PubMedGoogle Scholar
  112. Salliot C, Gottenberg JE, Bengoufa D, et al Anticentromere antibodies identify patients with Sjögren's syndrome and autoimmune overlap syndrome. J Rheumatol. 2007;34(11):2253–8PubMedGoogle Scholar
  113. Sankar V, Brennan MT, Kok MR, et al Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240–5PubMedCrossRefGoogle Scholar
  114. Simon BG, Moutsopoulos HM. Primary amyloidosis resembling sicca syndrome. Arthritis Rheum. 1979;22:932–4PubMedCrossRefGoogle Scholar
  115. Sjögren's Syndrome Foundation. And the survey says. The Moisture Seekers. 2006;24:1–3Google Scholar
  116. Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjögren's syndrome. Br J Rheumatol. 1994a;33:745–8CrossRefGoogle Scholar
  117. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum. 2000;29:296–304PubMedCrossRefGoogle Scholar
  118. Skopouli FN, Papanikolaou S, Malamou-Mitsi V, et al Obstetric and gynaecological profile in patients with primary Sjögren's syndrome. Ann Rheum Dis. 1994b;53:569–73CrossRefGoogle Scholar
  119. Skopouli FN, Talal A, Galanopoulou V, et al Raynaud's phenomenon in primary Sjögren's syndrome. J Rheumatol. 1990;17:618–20PubMedGoogle Scholar
  120. Stevens WJ, Swartele FE, Empsten FA, De Clerck LS. Use of the Saxon test as a measure of saliva production in a reference population of schoolchildren. Am J Dis Child. 1990;144:570–1PubMedGoogle Scholar
  121. Stojanovich L, Milovanovich B, de Luka SR, et al Cardiovascular auto-nomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjögren syndrome and other autoimmune diseases. Lupus. 2007;16: 181–5PubMedGoogle Scholar
  122. Takeda S, Haratake J, Kasai T, et al IgG4-associated idiopathic tubu-lointerstitial nephritis complicating autoimmune pancreatitis. Nephrol Dial Transplant. 2004;19:474–6PubMedCrossRefGoogle Scholar
  123. Taouli B, Brauner MW, Mourey I, et al Thin-section chest CT findings of primary Sjögren's syndrome: correlation with pulmonary function. Eur Radiol. 2002;12:1504–11PubMedCrossRefGoogle Scholar
  124. Terrier B, Lacroix C, Guillevin L, et al Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy. Arthritis Rheum. 2007;57(8):1520–9PubMedCrossRefGoogle Scholar
  125. Theander E, Manthorpe R, Jacobsson L. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum. 2004;50:1262–9PubMedCrossRefGoogle Scholar
  126. Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999;58:253–6PubMedCrossRefGoogle Scholar
  127. Trontzas PI, Andrianakos AA. Sjögren's syndrome: a population based study of prevalence in Greece. Ann Rheum Dis. 2005;64:1240–1PubMedCrossRefGoogle Scholar
  128. Tsampoulas CG, Skopouli FN, Sartoris DJ, et al Hand radiographic changes in patients with primary and secondary Sjögren's syndrome. Scand J Rheumatol. 1986;15:333–9PubMedCrossRefGoogle Scholar
  129. Tsianos EB, Chiras CD, Drosos AA, Moutsopoulos HM. Oesophageal dysfunction in patients with primary Sjögren's syndrome. Ann Rheum Dis. 1985;44:610–3PubMedCrossRefGoogle Scholar
  130. Tsianos EB, Tzioufas AG, Kita MD, et al Serum isoamylases in patients with autoimmune rheumatic diseases. Clin Exp Rheumatol. 1984;2: 235–8PubMedGoogle Scholar
  131. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum. 1996;39:767–72PubMedCrossRefGoogle Scholar
  132. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993;36: 340–7PubMedCrossRefGoogle Scholar
  133. Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron Y, et al Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. Ann Rheum Dis. 1996;55:116–21PubMedCrossRefGoogle Scholar
  134. Vitali C, Bombardieri Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis. 2002;61:544–58CrossRefGoogle Scholar
  135. Vivino FB, Gala I, Hermann GA. Change in final diagnosis on second evaluation of labial minor salivary gland biopsies. J Rheumatol. 2002;29:938–44PubMedGoogle Scholar
  136. Voulgarelis M, Dafni UG, Isenberg DA, Mousopoulos HM. Malignant lymphoma in primary Sjögren's syndrome. A multicenter, retrospective, clinical study by the European concerted action on Sjögren's syndrome. Arthritis Rheum. 1999;42:1765–72PubMedCrossRefGoogle Scholar
  137. Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006;65:1033–7PubMedCrossRefGoogle Scholar
  138. Walker J, Gordon T, Lester S, et al Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjögren's syndrome. J Rheumatol. 2003;30:2406–12PubMedGoogle Scholar
  139. Whitcher J, Gritz D, Daniels T. The dry eye: a diagnostic dilemma. Int Ophthal Clin. 1998;38:23–37PubMedCrossRefGoogle Scholar
  140. Wolkoff P, Nojgaard JK, Franck C, Skov P. The modern office environment desiccates the eyes? Indoor Air. 2006;16:258–65PubMedCrossRefGoogle Scholar
  141. Wright SA, Convery RP, Liggett N. Pulmonary involvement in Sjögren's syndrome. Rheumatology (Oxford). 2003;42:697–8PubMedCrossRefGoogle Scholar
  142. Wu AJ, Fox PC. Sjögren's syndrome. Semin Dermatol. 1994;13:138–43PubMedGoogle Scholar
  143. Yamamoto M, Takahashi H, Sugai S, Imai K. Clinical and pathological characteristics of Mikulicz's disease (IgG4-related plasmacytic exo-crinopathy). Autoimmun Rev. 2005;4:195–200PubMedCrossRefGoogle Scholar
  144. Zandbelt MM, de Wilde P, van Damme P, et al Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol. 2004;31:96–101PubMedGoogle Scholar
  145. Zintzaras E, Voulgarelis M, Moutsopoulos H. The risk of lymphoma development in autoimmune diseases. Arch Intern Med. 2005; 165:2337–44PubMedCrossRefGoogle Scholar
  146. Klippel JH, Stone JS, Crofford L, White P. Primer on the Rheumatic Diseases. 13th Edition. 2008. Springer. LondonCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Manuel Ramos-Casals
    • 1
  • Troy E. Daniels
    • 2
  • Robert I. Fox
    • 3
  • John P. Whitcher
    • 4
  • George E. Fragoulis
    • 5
  • Fotini N. Skopouli
    • 5
  • Haralampos M. Moutsopoulos
    • 5
  1. 1.Servei de Malalties Autoimmunes, Hospital ClínicC/VillarroelSpain
  2. 2.University of California at San Franscisco School of Medicine and Dentistry, Orofacial SciencesSan Francisco
  3. 3.Rheumatology Clinic, Scripps Memorial HospitalLa JollaUSA
  4. 4.University of Californa-San Francisco Department of OphthalmologySan FranciscoCalifornia
  5. 5.National University of Athens Medical School Department of PathophysiologyAthensGreece

Personalised recommendations